ATRA

Atara Biotherapeutics, Inc

4.96

USD

ATRA Earnings Reports

Positive Surprise Ratio

ATRA beat 19 of 41 last estimates.

46%

Next Report

Date of Next Report

May 13, 2026

Estimate for Q1 26 (Revenue/ EPS)

$1.73M

-$0.41

Implied change from Q4 25 (Revenue/ EPS)

+8.71%

+64.00%

Implied change from Q1 25 (Revenue/ EPS)

-98.23%

-111.71%

Atara Biotherapeutics, Inc earnings per share and revenue

On Mar 16, 2026, ATRA reported earnings of -0.25 USD per share (EPS) for Q4 25, missing the estimate of -0.17 USD, resulting in a -43.02% surprise. Revenue reached 1.59 million, compared to an expected 2.52 million, with a -36.82% difference. The market reacted with a +10.39% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 4 analysts forecast an EPS of -0.41 USD, with revenue projected to reach 1.73 million USD, implying an increase of 64.00% EPS, and increase of 8.71% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

TELA Bio, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.16

Surprise

+14.12%

BioCardia, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.17

Actual

-$0.06

Surprise

+65.40%

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Absci Corporation Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.23

Surprise

-16.04%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

LENZ Therapeutics, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.99

Actual

-$1.15

Surprise

-17.10%

Fennec Pharmaceuticals Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

$0.03

Actual

-$0.11

Surprise

-408.12%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

FAQ

What were Atara Biotherapeutics, Inc's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Atara Biotherapeutics, Inc reported EPS of -$0.25, missing estimates by -43.02%, and revenue of $1.59M, -36.82% below expectations.

How did the market react to Atara Biotherapeutics, Inc's Q4 2025 earnings?

The stock price moved up 10.39%, changed from $4.91 before the earnings release to $5.42 the day after.

When is Atara Biotherapeutics, Inc expected to report next?

The next earning report is scheduled for May 13, 2026.

What are the forecasts for Atara Biotherapeutics, Inc's next earnings report?

Based on 4 analysts, Atara Biotherapeutics, Inc is expected to report EPS of -$0.41 and revenue of $1.73M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.